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Abstract  22 
 23 
Objective: We wanted to exam the steady-state energy balance by using high fat diet-induced 24 
obese (DIO) rats and mice as models for positive energy balance, and gastric bypassed (GB) 25 
rats and gene knockout of muscarinic acetylcholine M3 receptor (M3KO) mice as models for 26 
negative energy balance. Methods: 132 rats and mice were used. Energy balance was 27 
measured by a comprehensive laboratory animal monitoring system. Gene expression was 28 
analysed by in situ hybridization in M3KO mice. Results: DIO rats reached the plateau of 29 
body weight 28 weeks after starting high-fat diet (25% heavier than controls), whereas DIO 30 
mice reached the plateau after 6 weeks (23% heavier than controls). At the plateau, DIO rats 31 
had higher calorie intake during light phase but not during dark phase, while mice had the 32 
same calorie intake per day as controls. DIO rats and mice had lower energy expenditure (EE) 33 
and respiratory exchange ratio (RER) than controls. GB-rats reached the plateau (15% weight 34 
loss) 2 weeks after surgery and had the same calorie intake as sham-operated controls. EE, but 35 
not RER, was higher in GB rats than controls during dark phase. The lean M3KO mice (25% 36 
lighter than wild-type (WT) mice at the plateau between 6-15 months of age) had the same 37 
calorie intake but higher EE, RER and hypothalamic mRNA expression of NPY, AgRP and 38 
leptin receptor than WT mice. Conclusion: When body weight gain or loss reached a plateau, 39 
the steady-state energy balance was mainly maintained by EE and/or RER rather than calorie 40 
intake.  41 
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Introduction 46 
The number of overweight individuals is increasing, leading to a global obesity 47 
epidemic [1, 2]. This is of concern because obesity is a major contributor in the development 48 
of type 2 diabetes, cardiovascular diseases, certain forms of cancer, overall reduced quality of 49 
life and premature mortality [3, 4]. Currently, weight loss treatments include diet control, 50 
physical training, drug therapies, and bariatric surgery [5]. Weight loss resulting from either 51 
dieting or exercise remains usually for a shorter period of time, whereas weight loss after 52 
bariatric surgery (such as sleeve gastrectomy or gastric bypass) has much longer effect [6, 7]. 53 
With intensive lifestyle interventions, a majority of obese participants in clinical trials lose 54 
7% to 10% of their initial weight at 1 year, but longer-term weight maintenance is difficult [8, 55 
9]. The development of anti-obesity drugs to target energy balance by acting on either 56 
appetite control or energy expenditure (EE) is yet without great success [9, 10, 11, 12]. For 57 
example, the pharmacological interventions reduce body weight only by 3-9% of initial 58 
weight on average at 1 year and the proportion of patients achieving clinically meaningful 59 
(>5%) weight loss ranges from 37% to 70% depending on different drugs and/or dosages [9]. 60 
In order for current lifestyle interventions, drug therapies and bariatric surgeries to be 61 
maximally effective for body weight control in individual patients as well as in a patient 62 
population, better understanding of the energy balance is essential [13, 14]. 63 
The concept of energy balance for regulating body weight is simple in principle. When 64 
energy output equals input, i.e., energy homeostasis, the body is at steady state energy 65 
balance. A new set point for steady state balance occurs when energy intake (EI) exceeds EE 66 
over a given period of time and weight is gained, or when EE exceeds EI and weight is lost 67 
[15]. In this study, we defined the dynamic phase of energy balance as weight gain or loss of 68 
more than 5% for at least one week, and steady state as less than 5% change in body weight 69 
for at least one week. From the energy balance point of view, it has not been understood why 70 
it is easier to control the body weight during the dynamic phase of energy balance than to 71 
reverse it under the steady state condition [16].  In fact, it is not uncommon that many obese 72 
patients seek weight-loss treatments when they are under the steady state in terms of body 73 
weight. Thus, a better understanding of steady-state energy balance may help us to better 74 
understand why it is difficult to perturb a shift in EE particularly to achieve a long-term body 75 
weight loss by either dieting or exercise after obesity is established.  76 
Previously, we and others have shown that dynamic development of obesity is 77 
associated with increased calorie per meal [17, 18], and that there are compensatory changes 78 
in hypothalamic gene expression of AgRP and NPY in rodents fed high-fat diet or low-energy 79 
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dense diet for a prolonged period of time, which is indicative of defence against changes in 80 
body weight [19, 20, 21, 22]. Gastric bypass-induced weight loss is mainly associated with 81 
increasing EE rather than reducing EI [23, 24, 25, 26, 27], which is in line with the 82 
hypothalamic gene expression of AgRP, NPY and POMC [28]. However, the initial report on 83 
M3KO mice showed a reduced food intake with increased expression of hypothalamic AgRP 84 
mRNA and reduced POMC mRNA [29], which is inconsistent with homeostatic mechanism 85 
of food intake regulation [30].   86 
In the present study, we wanted to explore the steady-state energy balance to defend a 87 
change in body weight in response to either positive or negative energy balance. Thus, we 88 
used high-fat-diet fed rats and mice as models for positive energy balance displaying an obese 89 
phenotype [31], and  gastric bypassed (GB) rats and gene knockout of muscarinic 90 
acetylcholine M3 receptor (M3KO) mice as models for negative energy balance [23, 32]. 91 
 92 
 93 
Materials and Methods  94 
Experimental design  95 
Four sets of experiments were conducted in rodent models, comprising two sets 96 
examining obesity development in rats and mice, and another two sets examining weight loss 97 
in rats and mice.   98 
All animals were housed in groups of three or four together in individually ventilated 99 
cages (1500 cm2 in size) on wood chip bedding with a 12 h light/dark cycle, room 100 
temperature of 21-22ºC and 50-60% relative humidity. The standard housing conditions were 101 
specific pathogen free and in agreement with FELASA (Federation of European Laboratory 102 
Animal Science Association) recommendations. Throughout the experiment, all animals had 103 
free access to tap water and food regardless of being in metabolic or Makrolon cages. The 104 
high fat diet (D12492) was purchased from Research Diets Inc. (New Brunswick, NJ, USA), 105 
and the normal chow (RM1 811004) was purchased from Scanbur BK AS (Sweden). Animal 106 
experiments were performed according to the guidelines for the design and statistical analysis 107 
of experiments using laboratory animals after being approved by the Norwegian National 108 
Animal Research Authority (Forsøksdyrutvalget, FDU). 109 
Diet-induced obese rats: Four weeks old male Sprague-Dawley rats were purchased 110 
from Taconic (Ejby, Denmark). The rats were divided into two groups: diet-induced obese 111 
(DIO) (n=12) and controls (n=8). To allow the DIO rats to adapt to high-fat diet, they were 112 
put on a mixture of 50% high fat diet and 50% normal chow for two weeks before being fed 113 
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high fat diet only (60% fat) [17]. The DIO and control rats received high fat diet or normal 114 
chow, respectively, throughout the study. Body weight was measured every week from arrival 115 
until euthanization. Food intake, eating behaviour, metabolic parameters and body 116 
composition were measured when the body weight-plateau was reached (35 weeks of age). To 117 
follow the 3R principle, this group of rats were also used in a separated study entitled “Time-118 
restricted feeding during weekdays against obesity: a study using high-fat diet-induced obese 119 
rat models” (Olsen MK, Choi MH, Kulseng B, Zhao C-M, Chen D. unpublished data).  120 
Diet-induced obese mice: Five weeks old male C57BL/6J mice were purchased from 121 
Jackson Laboratory (Bar Harbor, ME, USA). The mice were divided into two groups: DIO 122 
(n=10) and controls (n=10). To allow the DIO mice to adapt to the high-fat diet, they were fed 123 
a mixture of 50% high fat diet and 50% normal chow diet for two weeks before being fed 124 
high fat diet only (60% fat) for the remainder of the study. The control mice were fed normal 125 
chow for the entire study. Body weight was measured every week from arrival until 126 
euthanization. Food intake, eating behaviour, metabolic parameters and body composition 127 
was measured when the body weight-plateau was reached (11 weeks of age). 128 
Gastric bypassed rats: 48 weeks old male Sprague-Dawley rats were purchased from 129 
Taconic (Ejby, Denmark) and were divided into two groups: GB (n=14) and sham operation 130 
(n=6). The GB was performed according to previous experiments [25] and the rats were fed 131 
normal-chow throughout the whole study. Food intake, eating behaviour and metabolic 132 
parameters were measured when the body weight-plateau had been reached (3 weeks post-133 
surgery). To follow the 3R principle, the data from this group of rats were taken from our 134 
previous study [23] and re-analysed and re-used in the present study.  135 
M3 receptor knockout (M3KO) mice: M3KO mice were generated [33] and 136 
backcrossed 14 generations onto C57BL/6J background at Prof. Takeuchi’s laboratory (Kyoto 137 
Pharmaceutical University, Japan) and imported to Norway by Prof. D. Chen for this study. 138 
The M3KO mice were further bred through sibling matings for 2 generations. Age-matched 139 
wild-type (WT) mice on the same background (C57BL/6J) were purchased from Taconic 140 
(Ejby, Denmark). All the mice including M3KO and WT mice were fed normal chow in-141 
house together during the study period. Body weight was measured at 2, 6, 11 and 15 months 142 
of age. At 2 months of age there were 7 mice in each group, 3:4 male:female ratio in M3KO 143 
group and 4:3 male:female ratio in WT group. At 6, 11 and 15 months of age there were 8 144 
mice in each group, with male:female ratio of 4:4 ratio in the WT group, and 4:4, 5:3 and 6:2 145 
in the M3KO group, respectively. Brain tissue from 15 months old mice was collected for in 146 
situ hybridization. 147 
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Measurements of energy balance by CLAMS 148 
The parameters for energy balance were measured by a Comprehensive Laboratory 149 
Animal Monitoring System.  150 
The animals were acclimatized to the Comprehensive Laboratory Animal Monitoring 151 
System (CLAMS; Columbus Instruments International, Columbus, OH USA) for 24 h before 152 
data collection. At data collection the animals were kept in CLAMS for 48 h and data from 153 
the last 24 h were used for analysis. Before CLAMS the animals were habituated to their 154 
normal food as powder for three days, as the food in CLAMS is in powder form. The animals 155 
were placed in CLAMS when the body weight had reached a plateau. This is defined by less 156 
than 5% weight loss or gain over a period of 7 days or more. The DIO rats and mice were 157 
placed in CLAMS at 35 and 11 weeks of age, respectively, together with their respective 158 
control groups. GB and control rats were placed in CLAMS 3 weeks post-surgery, while 159 
M3KO and WT mice were 6, 11 and 15 months old when placed in CLAMS. 160 
Animals were placed in CLAMS with free access to standard powder food (RM1 161 
801002, Scanbur BK AS, Sweden) or to high fat diet, and tap water. This system is composed 162 
of a four-chamber open circuit indirect calorimeter designed for continuous monitoring of 163 
individual animals. Eating behaviour and metabolic parameters were recorded automatically. 164 
High-resolution feeding data was generated by monitoring all feeder balances every 0.5 165 
seconds. The end of an eating event (meal) was determined when the balances were stable for 166 
more than 10 seconds and a minimum of 0.05 g of food were eaten. An air sample was 167 
withdrawn every 5 min. The EE (kcal/h) was calculated according to this equation: 168 
(3.815+1.232 RER) × VO2, where RER (respiratory exchange ratio) was the volume of CO2 169 
produced per volume of O2 consumed. VO2 was the volume of O2 consumed per hour per 170 
kilogram of mass of the animal. Parameters that were obtained during light phase (7 am–7 171 
pm) and dark phase (7 pm–7 am) for each individual animal included number of meals, meal 172 
size, meal duration, accumulated food intake, intermeal interval, rate of eating, satiety ratio, 173 
drinking activity, EE and ambulatory activity. The intermeal interval was defined as the 174 
interval in minutes between two meals. Rate of eating was calculated by dividing the average 175 
meal size by the average duration of a meal, and satiety ratio, an index of the non-eating time 176 
produced by each gram of food consumed, was calculated by dividing the average intermeal 177 
interval by the average meal size. 178 
 179 
 180 
 181 
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Measurement of body composition 182 
Body composition was determined for DIO rats and mice, and respective control 183 
groups, using dual energy X-ray absorptiometry (DXA) with small animal software (Hologic 184 
QDR 4500A, Hologic Inc., Bedford, MA, USA). Total bone area (cm2), total fat mass (g) and 185 
total fat-free mass (g) were measured, and total mass (g), lean percentage (%) and fat 186 
percentage (%) were calculated. DXA was performed under anaesthesia (isoflurane). 187 
 188 
In situ hybridization 189 
Brain samples were taken at euthanization and snap-frozen in isopentane on dry ice 190 
before being stored at -80°C wrapped in aluminium foil. The frozen brains were cut (14 µm) 191 
in the region spanning the hypothalamus between Bregma –0.10 to –2.54 mm according to the 192 
Mouse Brain Atlas of Franklin & Paxinos 1997 and sections were mounted onto poly-L-193 
lysine-coated slides.  Primers for the amplification of AgRP spanned were based on Genbank 194 
sequence U89484 to amplify the sequence between bases 113-341 (forward primer 5’-195 
TGTTCCCAGAGTTCCCAGGTC-3’, reverse primer 5’-196 
GCATTGAAGAAGCGGCAGTAGCAC-3’). Primers for the amplification of POMC were 197 
based on Genbank sequence J00162 to amplify the sequence between bases 263-665 (forward 198 
primer 5’-GGGCAAGCGCTCCTACTCCAT-3’, reverse primer 5’-199 
GCCCTTCTTGTRSRCGTTCTTGA-3’). The DNA sequence for NPY was a full-length 200 
cloned rat NPY gene sequence. Primers for the amplification of Ob-Rb (leptin receptor)  were 201 
based on Genbank sequence U49107 to amplify the sequence between bases 5'-202 
GTGTGAGCATCTCTCCTGGAG-3' (+2829 to +2849) and 5'-203 
ACCACACCAGACCCTGAAAG-3' (+3362 to +3343)(see MCH information).  Integrated 204 
optical density (IOD) was obtained by reference to the 14C microscale. Values were averaged 205 
for each animal.  206 
 207 
Statistical analysis 208 
The results are expressed as means ± SEM. Statistical comparisons were performed 209 
using two-sided independent t-test between the groups, and paired t-test was used for 210 
comparisons within groups. If assumption of normal distribution was not met, Mann-Whitney 211 
U test (denoted as U test when applied) were used. A p-value of <0.05 was considered 212 
statistically significant. Shapiro-Wilk test was used to test for normal distribution and 213 
Levine’s test for homogeneity was used to test for equal variances between the groups and p-214 
values were reported accordingly. A power of >0.80 was set as minimal to ensure sufficient 215 
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sample sizes and were calculated using G*Power version 3.1 and a randomization table was 216 
used to assign the animals to different groups. The data analysis was performed in SPSS 217 
version 20.0.  218 
 219 
 220 
Results 221 
Diet-induced obese rats 222 
The increase of body weight reached the plateau 28 weeks after starting high-fat diet 223 
feeding (33 weeks of age). DIO rats were 25% heavier than age-matched and normal diet 224 
(ND) controls at the plateau (p=0.001) (Fig. 1a, Supplementary Table S1).  225 
 At 35 weeks of age, the rats were placed in CLAMS, and we found calorie intake was 226 
higher during dark phase than light phase in both ND (p<0.001) and DIO (p<0.001) rats 227 
indicating a good sensitivity of CLAMS. Calorie intake was slightly higher in DIO rats than 228 
ND rats during light phase (p=0.039), but not significantly different during the dark phase 229 
(p=0.083) (Fig. 1b). EE was higher during dark phase than light phase in ND rats (p<0.001). 230 
However, there were no differences between ND and DIO rats during light phase (p=0.917), 231 
but there was a trend for lower EE in DIO rats during dark phase (p=0.068) (Fig. 1c). RER 232 
was higher during dark phase than light phase in control rats (p<0.001). In comparison with 233 
ND rats, DIO rats had a lower RER during both light- and dark-phase (p=0.008 and <0.001, 234 
respectively)(Fig. 1d). Body composition analysis showed that total body mass (p<0.001) and 235 
surface area (p<0.001), fat mass (p<0.001, U test) and fat percentage (p<0.001) were higher, 236 
whereas the lean percentage (p<0.001) (but not lean mass (p=0.657, U test)) was lower in 237 
DIO than ND rats (Fig. S1).  238 
 239 
Diet-induced obese mice 240 
The increase of body weight reached the plateau 6 weeks after starting high-fat diet 241 
feeding (11 weeks of age). DIO mice were 23% heavier than age-matched and normal diet 242 
controls at the plateau (p<0.001) (Fig. 2a, Supplementary Table S2).    243 
 At the plateau of body weight, the mice were placed in CLAMS. We found that calorie 244 
intake was higher during dark phase than light phase particularly in ND mice (p<0.001). 245 
There was no difference in calorie intake between DIO and ND mice neither during light 246 
phase (p=0.326) nor during dark phase (p=0.943) (Fig. 2b). EE was higher during dark phase 247 
than light phase in both ND (p<0.001) and DIO (p<0.001) mice, suggesting higher active EE. 248 
There was no difference in the EE during light phase (p=0.274), but DIO had lower EE than 249 
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ND during dark phase (p=0.043) (Fig. 2c). RER was higher during dark phase than light 250 
phase in both ND (p=0.001) and DIO (p=0.008) mice. In comparison with ND mice, DIO 251 
mice had a lower RER only during dark phase (p=0.003) (Fig. 2d). Body composition 252 
analysis showed that total body mass (p<0.001) and surface (p=0.004), and fat mass (p<0.001, 253 
U test) and percentage (p<0.001) were higher, whereas the lean mass (p=0.020) and 254 
percentage (p<0.001) were lower in DIO than ND mice (Fig. S2). 255 
 256 
Gastric bypassed rats 257 
GB-induced body weight loss reached the plateau, i.e., 15% weight loss, 2 weeks after 258 
surgery (p<0.001)(Fig. 3a, Supplementary Table S3), and 3 weeks post-surgery, the rats were 259 
placed in CLAMS. Calorie intake was higher during dark phase than light phase in both 260 
sham-operated and GB rats (p=0.001 and 0.003, respectively). There was no difference in 261 
calorie intake between the two groups neither during light phase nor during dark phase 262 
(p=0.289 and 0.870, respectively) (Fig. 3b). EE was higher in GB rats than sham-operated rats 263 
during dark phase (p=0.033) (Fig. 3c). RER was higher during dark phase than light phase in 264 
both sham- and GB-operated group (p=0.001 and 0.008, respectively). There was no 265 
difference in RER between groups either during dark- or light-phase (p=0.389 and 0.516, 266 
respectively) (Fig. 3d).  267 
 268 
M3KO mice 269 
At the birth, the body weight did not differ between M3KO and WT mice [29]. At 2 270 
months of age there was a trend for lower body weight in M3KO than WT mice (p=0.065). 271 
The mice was placed in CLAMS at 6, 11 and 15 months of age, and M3KO mice weighed 272 
significantly less than WT mice at all time-points (p<0.001, 0.001 and 0.001, respectively). 273 
There was no significant difference in body weight between 6, 11, and 15 months of age (6 274 
vs. 11: p=0.599, 6 vs. 15: p=0.514 and 11 vs 15: p=0.292)(Fig. 4a). Both M3KO and WT 275 
mice had a continuous growth throughout the lifespan. (Supplementary Tables S4-6). Calorie 276 
intake was higher during dark phase than light phase in WT mice (p=0.002, 0.092 and 0.081, 277 
respectively) and more so in M3KO mice (p=0.022, 0.004 and <0.001, respectively). There 278 
were no differences in calorie intake between WT and M3KO mice at all time points 279 
examined, except light phase at 6 months where calorie intake was lower in M3KO compared 280 
to WT, (p=0.010) and dark phase at 15 months of age where calorie intake was unexpectedly 281 
higher in M3KO than WT mice ( p=0.034) (Fig. 4b).  Both EE and RER were higher during 282 
light- as well as dark-phase in M3KO than in WT mice at the time points measured (Light: 283 
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EE: p<0.001, =0.005 and =0.005, respectively. RER: p<0.001, =0.028 and <0.001, 284 
respectively) (Dark: EE: p<0.001, <0.001 and =0.003, respectively; RER: p<0.001, 0.001 and 285 
0.001, respectively) (Fig.4c, d).  286 
 In comparison with age-matched WT mice, the M3KO mice had higher mRNA 287 
expression of NPY, AgRP and leptin receptor in the arcuate nucleus in the hypothalamus 288 
(p=0.001, <0.001 and =0.003, respectively) (Fig. 5). Pro-opiomelanocortin (POMC) in the 289 
ARC and melanin-concentrating hormone (MCH) in ventromedial hypothalamus were 290 
unchanged in terms of mRNA expression (p=0.356 and 0.200, respectively) (Fig. 5).  291 
 292 
 293 
Discussion 294 
The results of the present study using 4 different animal models have demonstrated a 295 
common phenotype, i.e. steady-state energy balance at the plateau of body weight 296 
development. EE was measured during light- and dark-phases separately to indicate basal and 297 
active metabolic rates, respectively. Interestingly, the basal metabolic rate was unchanged in 298 
both obese rats and mice compared to normal chow-fed controls, but the active metabolic rate 299 
seemed to be reduced significantly in mice and non-significantly in rats (probably due to the 300 
sample size).  The results also showed a higher RER in dark phase than light phase during the 301 
steady-state energy balance, indicating a higher oxidative capacity of the muscle for the 302 
provision of energy in the dark phase [34]. Furthermore, the obese rats had a low RER during 303 
both light-and dark- phases, suggesting a lower muscle’s oxidative capacity. 304 
These results may help us to explain what we often see in clinic, i.e., the large 305 
variability in individual responses to weight loss interventions in patients could be because 306 
the differences in the time frame over which a steady-state energy balance establishes 307 
between individuals. This is in line with a recent study showing that the longer it took to reach 308 
a steady state following GB surgery, the greater the weight loss was. In addition, the majority 309 
of patients undergoing GB surgery did not lose significant weight after reaching steady state 310 
[35].  311 
 Previously it has been reported that NPY and AgRP mediate complementary functions 312 
of hyperphagia and reduce EE in leptin receptor deficient mice [36]. In addition, it has been 313 
demonstrated that there are compensatory changes in hypothalamus, particularly NPY and 314 
AgRP gene expression, in normal rats and mice fed either with high-fat diet or low-energy 315 
dense diet for long period, indicative of a compensation to defend the body weight changes 316 
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[19, 20, 21, 22]. Previously, we and others have shown that GB-induced weight loss in rats 317 
was not due to decreased calorie intake, but due to an increase in EE [23, 24, 25, 26, 27], 318 
which is in line with the hypothalamic gene expression of NPY, AgRP, or POMC [28]. 319 
Therefore, we did not analyse the hypothalamic gene expression in obese rats, obese mice and 320 
GB rats in the present study.  321 
 However, we further analysed the M3KO mouse model with respect to both energy 322 
balance and the hypothalamic gene expression. This was because in the initial publication 323 
[29] reported that M3KO mice had reduced food intake with increased expression of 324 
hypothalamic AgRP mRNA and decreased expression of POMC mRNA, which appeared to 325 
be inconsistent with the homeostatic mechanism of food intake regulation associated with the 326 
regulatory neuropeptides encoded by these genes[30]. In contrast to this previous study we 327 
found M3KO mice did not have significantly overall reduced calorie intake as measured using 328 
a more precise method (the state-of-the-art CLAMS) than one used in the study by Yamada et 329 
al. [29].  Furthermore, we found that reduced calorie intake during the light phase and 330 
increased calorie intake during the dark phase were accompanied by increase EE during both 331 
light phase and dark phases throughout all stages of growth and maturity. Additionally, in 332 
contrast to this previous study, we found that RER was increased in M3KO mice, implicating 333 
use of carbohydrates as the predominant fuel for cellular respiration. This may also suggest 334 
high rates of de novo lipogenesis in these mice as carbohydrates are partially oxidized and 335 
directed towards fatty acid synthesis. This would have a considerable effect on the fat mass of 336 
these mice and is highly relevant to their steady state. Similar to EE, RER was higher in both 337 
the light and dark phases. Taken together with the findings of equal body weights at birth and 338 
during the initial post-natal development, we suggest that the lean phenotype of the M3KO 339 
mice is not caused by prenatal factors or environment, but develops as the mice grow and is 340 
maintained as the mice achieve a new steady-state of energy balance. Since the absence of M3 341 
receptor has beneficial effects, which protect mice against obesity, some studies with new 342 
classes of M3-receptor selective antagonists have been initiated but still in its preliminary 343 
phases, and the lack of specific antagonists or agonists for M3 receptors in CNS, make it 344 
impossible to validate this anti-obesity target at present [37]. In addition, there are several 345 
other possible pharmacological treatments for obesity targeting EE, such as thyroid hormone 346 
receptor β agonists (GC-1 and GC-24) and NADPH:quinone reductase 1 (NQO1) activators 347 
(MB12066) [38, 39]. Some of these compounds have shown promising results as obesity 348 
treatment in animal studies, with MB12066 having completed Phase I clinical trial [40, 41, 349 
42]. 350 
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 The results of the present study suggest that when a body weight plateau is reached 351 
following either weight gain or loss, a new steady-state energy homeostasis occurs which is 352 
mainly due to alterations in EE and RER. The decreased EE in obese animals and increased 353 
EE in lean animal models suggest that interventions for reduction in body weight or for 354 
continuation of weight loss should target EE. 355 
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Figures Captions 543 
 544 
Figure 1 | (a) Body weight of high-fat-diet (HFD) induced obese (DIO) (n=12) rats relative to 545 
normal diet (ND) (n=8) rats from 5 to 35 weeks of age. Grey area represents body weight 546 
plateau (less than 5% increase or decrease in BW over last couple of weeks). CLAMS was 547 
performed at 35 weeks of age for both DIO (n=11) and ND (n=7) rats. (b) Calorie intake 548 
(g/100g body weight) during light phase and dark phase of DIO and ND rats. (c) EE 549 
(kcal/h/100g body weight) during light phase and dark phase of DIO and ND rats. (d) RER 550 
during light phase and dark phase of DIO and ND rats. White background indicates light 551 
phase and grey background indicates dark phase. Data is expressed as mean ± SEM. *, **, 552 
***: p<0.05, 0.01, 0.001 between DIO and ND. Independent t-test was used between groups 553 
and paired t-test within groups (light vs. dark phase). 554 
 555 
Figure 2 | (a) Body weight of high-fat-diet (HFD) induced obese (DIO) (n=10) mice relative 556 
to normal diet (ND) (n=10) mice from 5 to 12 weeks of age. Grey area represents body weight 557 
plateau (less than 5% increase or decrease in BW over last couple of weeks). CLAMS was 558 
performed at 11 weeks of age for both DIO (n=10) and ND (n=10) mice.  (b) Calorie intake 559 
(g/100g body weight) during light phase and dark phase of DIO and ND mice. (c) EE 560 
(kcal/h/100g body weight) during light phase and dark phase of DIO and ND mice. (d) RER 561 
during light phase and dark phase of DIO and ND mice. White background indicates light 562 
phase and grey background indicates dark phase. Data is expressed as mean ± SEM. **, ***:   563 
p< 0.01, 0.001 between DIO and ND. Independent t-test was used between groups and paired 564 
t-test within groups (light vs. dark phase). 565 
 566 
Figure 3 | (a) Body weight of GB-operated (n=14) rats relative to sham-operated (n=6) rats up 567 
to 5 weeks post-surgery. Grey area represents body weight plateau (less than 5% increase or 568 
decrease in BW over last couple of weeks). CLAMS was performed at 3 weeks after surgery 569 
for both GB (n=8) and sham-operated (n=6) rats. (b) Calorie intake (g/100g body weight) 570 
during light phase and dark phase of GB and sham rats. (c) EE (kcal/h/100g body weight) 571 
during light phase and dark phase of GB and sham rats. (d) RER during light phase and dark 572 
phase of GB and sham rats. White background indicates light phase and grey background 573 
indicates dark phase. Data is expressed as mean ± SEM. *, ** p<0.05, 0.01 between GB and 574 
sham. Independent t-test was used between groups and paired t-test within groups (light vs. 575 
dark phase). 576 
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 577 
Figure 4 | (a) Body weight of M3KO mice relative to wild-type (WT) (n=7) at 2 (n=8), 6 578 
(n=8), 11 (n=8) and 15 (n=8) months of age. Grey area represents body weight plateau (less 579 
than 5% increase or decrease in BW over last couple of weeks). CLAMS was performed at 6, 580 
11 and 15 months of age for both M3KO (n=8) and WT (n=8) mice. (b) Calorie intake 581 
(g/100g body weight) during light phase and dark phase of WT and M3KO mice at 6, 11 and 582 
15 months of age. (c) EE during light phase and dark phase of WT and M3KO mice at 6, 11 583 
and 15 months of age. (d) RER during light phase and dark phase of WT and M3KO mice at 584 
6, 11 and 15 months of age. 585 
 586 
Figure 5 | mRNA expression (integrated optical density, %IOD) of AgRP, NPY, POMC and 587 
leptin receptor (Lepr) in arcuate nucleus and of MCH in ventromedial hypothalamus of WT 588 
(n=8) and M3KO (n=8) mice at 15 months of age. Data is expressed as mean ± SEM. *, **, 589 
***: p<0.05, 0.01, 0.001 between M3KO and WT. Independent t-test was used between 590 
groups. 591 
 592 
Figure S1 | Body composition of DIO (n=11) and normal diet (ND) (n=8) rats at 35 weeks of 593 
age. (a) Total mass (g), (b) Fat mass (g), (c) Fat (%), (d) Surface area of the rats (cm2), (e) 594 
Lean mass (g) and (f) Lean (%). Data is expressed as mean ± SEM. **, ***:   p< 0.01, 0.001 595 
between DIO and ND. Independent t-test was used for all comparisons except for fat and lean 596 
mass where U test was used. 597 
 598 
Figure S2 | Body composition of DIO (n=10) mice and normal diet (ND) (n=10) mice at 11 599 
weeks of age. (a) Total mass (g), (b) Fat mass (g), (c) Fat (%), (d) Surface area of the rats 600 
(cm2), (e) Lean mass (g) and (f) Lean (%).  Data is expressed as mean ± SEM. *, **, ***:   p< 601 
0.05, 0.01, 0.001 between DIO and ND. Independent t-test was used for all comparisons 602 
except for fat mass where U test was used. 603 
 604 
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Supplementary Table S1 | Energy balance in normal diet (ND) and diet-induced obese 
(DIO) rats at 35 weeks of age. Data expressed as mean±SEM. Independent t-test was used for 
all comparisons. U –test were used if normality assumptions were not met (denoted U). 
Parameters ND (n=7) DIO (n=11) p-value (two-tailed) 
24 Hours 
Food Intake (g) 15.05±1.05 12.84±0.97 0.155 
Food Intake (g/100g body weight) 2.49±0.18 1.73±0.13 0.004u 
Calories intake (kcal) 38.67±2.71 67.3±5.07 0.001 
Calories intake (kcal/100g body weight) 6.41±0.45 9.05±0.69 0.008u 
Number of meals 64.29±7.61 24.64±1.92 0.002 
Meal size (g/meal) 0.25±0.03 0.54±0.05 0.000 
Meal size (kcal/meal) 0.64±0.07 2.85±0.27 0.000 
Meal duration (min) 82.22±5.1 33.72±1.85 0.000 
Meal duration (min/meal) 1.39±0.16 1.44±0.12 0.771 
Intermeal interval (min) 22.84±3.08 58.31±4.73 0.000 
Satiety ratio (min/g) 91.27±6.15 115.6±14.95 0.246u 
Rate of eating (g/min) 0.19±0.02 0.38±0.02 0.000 
Water intake (mL) 14.86±0.65 11.56±0.77 0.009 
Water intake (ml/100g body weight) 2.47±0.14 1.54±0.1 0.000 
Water intake during one interval (ml/time) 0.96±0.14 0.96±0.11 0.988 
Energy expenditure (kcal/h) 2.19±0.13 2.53±0.12 0.084 
Energy expenditure (kcal/h/100g body weight) 0.36±0.01 0.34±0.01 0.219 
Energy expenditure (kcal/h/cm2 body surface) 0.004±0 0.004±0 0.970 
RER 0.89±0.01 0.78±0.01 0.000 
VO2 733.04±25.46 702.51±25.88 0.438 
VCO2 653.15±29.62 549.67±21.47 0.011 
Ambulatory activity 8059.8±225.77 5736±257.01 0.104u 
     
Parameters ND (n=7) DIO (n=11) p-value (two-tailed) 
Light Phase 
Food Intake (g) 1.26±0.49 2.23±0.52 0.328u 
Food Intake (g/100g body weight) 0.21±0.08 0.3±0.07 0.423 
Calories intake (kcal) 3.23±1.27 11.67±2.75 0.035u 
Calories intake (kcal/100g body weight) 0.55±0.2 1.52±0.38 0.039 
Number of meals 6.57±1.85 5.09±0.96 0.445 
Meal size (g/meal) 0.17±0.04 0.39±0.07 0.033 
Meal size (kcal/meal) 0.45±0.09 2.04±0.36 0.001 
Meal duration (min) 6.08±1.93 6.1±1.52 0.996 
Meal duration (min/meal) 0.89±0.13 1.08±0.12 0.322 
Intermeal interval (min) 141.98±40.4 155.39±27.7 0.780 
Satiety ratio (min/g) 1265.18±653.95 3650.66±3232.5 0.285u 
Rate of eating (g/min) 0.19±0.02 0.36±0.04 0.004 
Water intake (mL) 0.15±0.08 0.9±0.28 0.044u 
Water intake (ml/100g body weight) 0.03±0.01 0.11±0.03 0.085u 
Water intake during one interval (ml/time) 0.07±0.04 0.4±0.11 0.027u 
Energy expenditure (kcal/h) 1.99±0.11 2.45±0.1 0.009 
Energy expenditure (kcal/h/100g body weight) 0.33±0.01 0.33±0.01 0.917 
Energy expenditure (kcal/h/cm2 body surface) 0.003±0 0.003±0 0.044u 
RER 0.85±0.02 0.78±0.01 0.008 
VO2 673.28±19.97 681.08±21.43 0.807 
VCO2 572.11±26.3 531.86±18.05 0.210 
Ambulatory activity 1486.4±94.14 1516.89±88.74 0.596u 
     
Parameters ND (n=7) DIO (n=11) p-value (two-tailed) 
Dark Phase 
Food Intake (g) 13.79±0.95 10.62±0.9 0.033 
Food Intake (g/100g body weight) 2.28±0.15 1.43±0.12 0.000 
Calories intake (kcal) 35.44±2.45 55.63±4.72 0.002 
Calories intake (kcal/100g body weight) 5.86±0.4 7.47±0.64 0.083 
Number of meals 57.71±6.75 19.55±2.23 0.001 
Meal size (g/meal) 0.26±0.03 0.6±0.07 0.000 
Meal size (kcal/meal) 0.66±0.07 3.14±0.35 0.000 
Meal duration (min) 76.13±4.81 27.62±1.5 0.000 
Meal duration (min/meal) 1.43±0.17 1.6±0.18 0.536 
Intermeal interval (min) 12.04±1.66 38.94±5.23 0.000u 
Satiety ratio (min/g) 47.09±3.15 67.18±7.04 0.020u 
Rate of eating (g/min) 0.19±0.02 0.38±0.02 0.000 
Water intake (mL) 14.71±0.61 10.67±0.62 0.001u 
Water intake (ml/100g body weight) 2.44±0.13 1.43±0.09 0.000 
Water intake during one interval (ml/time) 1.05±0.16 1.08±0.13 0.897 
Energy expenditure (kcal/h) 2.39±0.16 2.61±0.14 0.345 
Energy expenditure (kcal/h/100g body weight) 0.39±0.02 0.35±0.02 0.068 
Energy expenditure (kcal/h/cm2 body surface) 0.004±0 0.004±0 0.429 
RER 0.92±0.01 0.78±0.01 0.000 
VO2 792.8±32.26 723.93±32.88 0.177 
VCO2 734.19±34.67 567.49±26.79 0.001 
Ambulatory activity 6573.4±296.45 4219.11±267.14 0.104u 
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Supplementary Table S2 | Energy balance in normal diet (ND) and diet-induced obese 
(DIO) mice at 11 weeks of age. Data expressed as mean±SEM. Independent t-test was used 
for all comparisons. U –test were used if normality assumptions were not met (denoted U). 
Parameters ND (n=10) DIO (n=10) p-value (two-tailed) 
24 Hours 
Food Intake (g) 4.22±0.61 3.07±1.13 0.063u 
Food Intake (g/100g body weight) 15.25±2.27 8.91±3.18 0.035u 
Calories intake (kcal) 10.84±1.56 16.07±5.91 0.353u 
Calories intake (kcal/100g body weight) 39.19±5.83 46.69±16.67 0.280u 
Number of meals 85.3±7.71 61.7±8.45 0.054 
Meal size (g/meal) 0.05±0 0.04±0.012 0.105u 
Meal size (kcal/meal) 0.13±0.01 0.11±0.03 0.105u 
Meal duration (min) 105.27±11.07 32.23±5.66 0.000 
Meal duration (min/meal) 1.24±0.07 0.51±0.044 0.000 
Intermeal interval (min) 16.54±1.4 27.7±4.78 0.048 
Satiety ratio (min/g) 361.8±42.88 970.82±208.87 0.017 
Rate of eating (g/min) 0.04±0.01 0.09±0.022 0.029u 
Water intake (mL) 2.21±0.05 1.68±0.18 0.018 
Water intake (ml/100g body weight) 7.99±0.26 5.15±0.72 0.002 
Water intake during one interval (ml/time) 0.05±0 0.07±0.021 0.280u 
Energy expenditure (kcal/h) 0.4±0.01 0.44±0.026 0.023u 
Energy expenditure (kcal/h/100g body weight) 1.45±0.04 1.31±0.085 0.165u 
Energy expenditure (kcal/h/cm2 body surface) 0±0 0.05±0 0.796u 
RER 0.91±0.03 0.81±0.031 0.016 
VO2 2941.72±89.33 2718.82±170.02 0.529u 
VCO2 2702.743±92.59 2210.76±182.3 0.027 
Ambulatory activity 11262.8±2522.14 10998.4±1933.35 0.436u 
     
 
Parameters ND (n=10) DIO (n=10) p-value (two-tailed) 
Light Phase 
Food Intake (g) 1.14±0.2 1.15±0.42 0.165u 
Food Intake (g/100g body weight) 4.12±0.75 3.29±1.18 0.075u 
Calories intake (kcal) 2.94±0.52 6±2.21 0.684u 
Calories intake (kcal/100g body weight) 10.59±1.93 17.25±6.17 1.000u 
Number of meals 28.1±3.03 17.4±2.32 0.012 
Meal size (g/meal) 0.04±0 0.06±0.02 0.739u 
Meal size (kcal/meal) 0.1±0.01 0.15±0.05 0.739u 
Meal duration (min) 31.15±2.92 6.87±1.37 0.000u 
Meal duration (min/meal) 1.15±0.1 0.38±0.04 0.000 
Intermeal interval (min) 25.83±2.49 43.87±4.7 0.005 
Satiety ratio (min/g) 685.11±73.44 1420.31±335.79 0.059 
Rate of eating (g/min) 0.04±0.01 0.19±0.08 0.001u 
Water intake (mL) 0.67±0.04 0.62±0.11 0.692 
Water intake (ml/100g body weight) 2.41±0.15 1.93±0.39 0.264 
Water intake during one interval (ml/time) 0.05±0 0.05±0.01 0.436u 
Energy expenditure (kcal/h) 0.36±0.01 0.41±0.02 0.140 
Energy expenditure (kcal/h/100g body weight) 1.31±0.04 1.21±0.08 0.274 
Energy expenditure (kcal/h/cm2 body surface) 0±0 0±0 0.684u 
RER 0.85±0.03 0.79±0.03 0.190u 
VO2 2701.94±87.25 2521.09±161.52 0.338 
VCO2 2303.14±96.38 1994.48±161.82 0.105u 
Ambulatory activity 2780.08±659.06 3022.8±570.81 0.785 
     
 
Parameters ND (n=10) DIO (n=10) p-value (two-tailed) 
Dark Phase 
Food Intake (g) 3.07±0.45 1.92±0.72 0.035u 
Food Intake (g/100g body weight) 11.13±1.68 5.62±2.06 0.007u 
Calories intake (kcal) 7.9±1.16 10.07±3.8 0.315u 
Calories intake (kcal/100g body weight) 28.59±4.31 29.44±10.78 0.280u 
Number of meals 57.2±5.44 44.3±6.67 0.151 
Meal size (g/meal) 0.05±0.01 0.04±0.01 0.052u 
Meal size (kcal/meal) 0.14±0.01 0.1±0.03 0.052u 
Meal duration (min) 74.12±10.46 25.36±5 0.001 
Meal duration (min/meal) 1.28±0.1 0.55±0.05 0.000 
Intermeal interval (min) 12.24±1.45 20.42±4.43 0.247u 
Satiety ratio (min/g) 253.23±42.66 741.89±156.87 0.013 
Rate of eating (g/min) 0.05±0.01 0.07±0.02 0.165u 
Water intake (mL) 1.54±0.05 1.06±0.08 0.000u 
Water intake (ml/100g body weight) 5.58±0.24 3.23±0.36 0.000u 
Water intake during one interval (ml/time) 0.06±0 0.08±0.03 0.190u 
Energy expenditure (kcal/h) 0.44±0.02 0.48±0.03 0.075u 
Energy expenditure (kcal/h/100g body weight) 1.59±0.05 1.42±0.09 0.043u 
Energy expenditure (kcal/h/cm2 body surface) 0.01±0 0.01±0 0.796u 
RER 0.97±0.03 0.83±0.04 0.003 
VO2 3181.38±94.72 2916.54±186.14 0.579u 
VCO2 3102.16±108.17 2427.04±207.7 0.010 
Ambulatory activity 8482±1911.33 7975.6±1433.72 0436u 
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Supplementary Table S3 | Energy balance in sham- and gastric bypass (GB)-operated rats 3 
weeks post-surgery. Data expressed as mean±SEM. Independent t-test was used for all 
comparisons. U –test were used if normality assumptions were not met (denoted U). 
  Parameters Sham (n=6) GB (n=8) p-value (two-tailed) 
24 Hours 
Food Intake (g) 20.51±1.17 18.63±3.09 0.852u 
Food Intake (g/100g body weight) 3.57±0.24 3.72±0.6 0.345u 
Calories intake (kcal) 52.72±3 47.88±7.94 0.852u 
Calories intake (kcal/100g body weight) 9.18±0.63 9.56±1.53 0.345u 
Number of meals 44.83±4.48 44±6.95 0.928 
Meal size (g/meal) 0.48±0.04 0.39±0.06 0.323 
Meal size (kcal/meal) 1.22±0.11 1±0.16 0.323 
Meal duration (min) 58.43±7.37 65.15±11.08 0.648 
Meal duration (min/meal) 1.3±0.1 1.41±0.11 0.505 
Intermeal interval (min) 31.64±3.15 84.44±56.47 0.755u 
Satiety ratio (min/g) 66.85±3.71 914.52±847.79 0.852u 
Rate of eating (g/min) 0.37±0.03 0.28±0.05 0.184 
Water intake (mL) 20.22±1.83 17.85±2.38 0.472 
Water intake (ml/100g body weight) 3.5±0.31 3.61±0.49 0.865 
Water intake during one interval (ml/time) 2.09±0.2 1.32±0.17 0.013 
Energy expenditure (kcal/h) 1.92±0.07 1.86±0.05 0.852u 
Energy expenditure (kcal/h/100g body weight) 0.33±0.01 0.38±0.01 0.003 
Energy expenditure (kcal/h/cm2 body surface) 0.003±0 0.003±0 0.055 
RER 0.97±0.01 0.94±0.04 0.852u 
VO2 663.32±16.09 755.31±15.33 0.005u 
VCO2 638.31±17.4 707.19±27.26 0.020u 
Ambulatory activity 6423.33±375.13 6186±623.55 0.770 
     
  Parameters Sham (n=6) GB (n=8) p-value (two-tailed) 
Light Phase 
Food Intake (g) 4.35±0.54 4.99±0.91 0.593 
Food Intake (g/100g body weight) 0.75±0.09 1±0.18 0.289 
Calories intake (kcal) 11.18±1.39 12.82±2.35 0.593 
Calories intake (kcal/100g body weight) 1.93±0.23 2.57±0.46 0.289 
Number of meals 12.67±1.8 16.13±3.04 0.389 
Meal size (g/meal) 0.37±0.07 0.29±0.03 0.260 
Meal size (kcal/meal) 0.96±0.17 0.74±0.09 0.260 
Meal duration (min) 12.3±2.07 15.76±3.29 0.429 
Meal duration (min/meal) 1.02±0.19 0.9±0.1 0.552 
Intermeal interval (min) 57.05±8.2 80.3±40.2 0.414u 
Satiety ratio (min/g) 168.48±31.65 674.16±546.43 0.573u 
Rate of eating (g/min) 0.38±0.04 0.32±0.02 0.172 
Water intake (mL) 0.36±0.26 1.67±0.81 0.081u 
Water intake (ml/100g body weight) 0.06±0.04 0.34±0.16 0.008u 
Water intake during one interval (ml/time) 0.21±0.12 0.6±0.23 0.491u 
Energy expenditure (kcal/h) 2.08±0.03 1.9±0.06 0.029 
Energy expenditure (kcal/h/100g body weight) 0.36±0.01 0.38±0.01 0.126 
Energy expenditure (kcal/h/cm2 body surface) 0.003±0 0.003±0 0.824 
RER 0.94±0.01 0.91±0.03 0.389 
VO2 726.68±15.56 776.37±20.45 0.094 
VCO2 682.5±12.08 705.98±29.9 0.531 
Ambulatory activity 1636.17±103.11 1591.63±86.9 0.746 
    
Parameters Sham (n=6) GB (n=8) p-value (two-tailed) 
Dark Phase 
Food Intake (g) 16.16±1.3 13.64±2.44 0.426 
Food Intake (g/100g body weight) 2.82±0.26 2.72±0.47 0.870 
Calories intake (kcal) 41.54±3.34 35.06±6.28 0.426 
Calories intake (kcal/100g body weight) 7.24±0.67 6.99±1.2 0.870 
Number of meals 32.17±4.17 27.88±4.64 0.521 
Meal size (g/meal) 0.53±0.04 0.45±0.08 0.464 
Meal size (kcal/meal) 1.35±0.11 1.16±0.2 0.464 
Meal duration (min) 46.13±6.52 49.39±8.17 0.772 
Meal duration (min/meal) 1.43±0.06 1.77±0.16 0.086 
Intermeal interval (min) 22.2±3.06 63.6±42.28 0.852u 
Satiety ratio (min/g) 41.7±3.46 787.62±742.99 0.662u 
Rate of eating (g/min) 0.37±0.03 0.27±0.06 0.043u 
Water intake (mL) 19.86±1.77 16.18±1.86 0.108u 
Water intake (ml/100g body weight) 3.44±0.31 3.27±0.39 0.750 
Water intake during one interval (ml/time) 2.43±0.32 1.49±0.2 0.013u 
Energy expenditure (kcal/h) 1.75±0.14 1.82±0.1 0.414u 
Energy expenditure (kcal/h/100g body weight) 0.3±0.02 0.37±0.02 0.033 
Energy expenditure (kcal/h/cm2 body surface) 0.003±0 0.003±0 0.113 
RER 1±0.01 0.97±0.04 0.516 
VO2 600.02±36.7 734.01±37.61 0.029 
VCO2 594.19±37.54 708.2±40.76 0.070 
Ambulatory activity 4787.17±284.06 4594.38±555.18 0.785 
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Supplementary Table S4 | Energy balance in wild-type (WT) and M3KO mice at 6 months 
of age. Data expressed as mean±SEM. Independent t-test was used for all comparisons. U –
test were used if normality assumptions were not met (denoted U). 
 
Parameters WT (n=8) M3KO (n=8) p-value (two-tailed) 
24 Hours 
Food Intake (g) 4±0.24 3.49±0.51 0.380 
Food Intake (g/100g body weight) 12.33±0.8 14.69±1.79 0.249 
Calories intake (kcal) 10.28±0.62 8.97±1.31 0.380 
Calories intake (kcal/100g body weight) 31.68±2.06 37.75±4.61 0.249 
Number of meals 80.25±8.76 24±6.17 0.000 
Meal size (g/meal) 0.05±0.01 0.19±0.04 0.005 
Meal size (kcal/meal) 0.14±0.02 0.5±0.09 0.005 
Meal duration (min) 69.29±11.55 23.51±4.71 0.005 
Meal duration (min/meal) 0.86±0.09 1.5±0.51 0.130u 
Intermeal interval (min) 18.28±1.92 86.49±18.76 0.008 
Satiety ratio (min/g) 346.19±19.64 430.65±51.52 0.160 
Rate of eating (g/min) 0.07±0.01 0.18±0.03 0.002 
Water intake (mL) 2.61±0.2 3.46±0.68 0.267 
Water intake (ml/100g body weight) 8.03±0.63 14.94±2.9 0.050 
Water intake during one interval (ml/time) 0.07±0.01 0.06±0.01 0.539 
Energy expenditure (kcal/h) 0.44±0.01 0.4±0.01 0.028 
Energy expenditure (kcal/h/100g body weight) 1.34±0.03 1.71±0.04 0.000 
Energy expenditure (kcal/h/cm2 body surface) 0.005±0 0.005±0 0.000 
RER 0.89±0.01 1±0.01 0.000 
VO2 2742±67.57 3370.29±96.59 0.000 
VCO2 2440±57.88 3417.59±84.93 0.000 
Ambulatory activity 14323.75±3489.96 16439.88±4172.16 0.703 
     
 
Parameters WT (n=8) M3KO (n=8) p-value (two-tailed) 
Light Phase 
Food Intake (g) 1.55±0.11 0.93±0.27 0.005u 
Food Intake (g/100g body weight) 4.78±0.37 3.9±1.08 0.010u 
Calories intake (kcal) 3.98±0.28 2.38±0.71 0.005u 
Calories intake (kcal/100g body weight) 12.28±0.96 10.02±2.79 0.010u 
Number of meals 28.25±4.14 7.25±2.96 0.001 
Meal size (g/meal) 0.06±0.01 0.31±0.1 0.039 
Meal size (kcal/meal) 0.16±0.02 0.8±0.26 0.039 
Meal duration (min) 17.94±3.24 6.48±2.07 0.010 
Meal duration (min/meal) 0.65±0.09 2.57±1.4 0.878u 
Intermeal interval (min) 27.23±3.64 196.09±51.27 0.013 
Satiety ratio (min/g) 448.53±25.91 717.32±100.33 0.032 
Rate of eating (g/min) 0.11±0.03 0.35±0.12 0.084 
Water intake (mL) 0.65±0.09 0.62±0.1 0.859 
Water intake (ml/100g body weight) 2.01±0.31 2.71±0.43 0.212 
Water intake during one interval (ml/time) 0.06±0.01 0.05±0.01 0.431 
Energy expenditure (kcal/h) 0.38±0.01 0.36±0.01 0.045 
Energy expenditure (kcal/h/100g body weight) 1.18±0.04 1.53±0.04 0.000 
Energy expenditure (kcal/h/cm2 body surface) 0.004±0 0.005±0 0.000 
RER 0.84±0.01 0.94±0.01 0.000 
VO2 2457.6±77.21 3073.19±99.3 0.000 
VCO2 2059.68±72.3 2903.66±61 0.000 
Ambulatory activity 3964.83±401.03 4951.83±617.33 0.210 
     
 
Parameters WT (n=8) M3KO (n=8) p-value (two-tailed) 
Dark Phase 
Food Intake (g) 2.45±0.25 2.56±0.49 0.843 
Food Intake (g/100g body weight) 7.55±0.76 10.79±1.78 0.117 
Calories intake (kcal) 6.3±0.63 6.59±1.27 0.843 
Calories intake (kcal/100g body weight) 19.4±1.96 27.73±4.58 0.117 
Number of meals 52±5.69 16.75±3.44 0.000 
Meal size (g/meal) 0.05±0.01 0.18±0.03 0.003 
Meal size (kcal/meal) 0.13±0.02 0.47±0.08 0.003 
Meal duration (min) 51.35±8.6 17.03±3.25 0.005 
Meal duration (min/meal) 0.99±0.12 1.39±0.45 0.402 
Intermeal interval (min) 13.75±1.54 52.23±9.71 0.005 
Satiety ratio (min/g) 287.66±30.5 303.25±40.23 0.762 
Rate of eating (g/min) 0.06±0.01 0.18±0.03 0.005 
Water intake (mL) 1.96±0.17 2.84±0.6 0.198 
Water intake (ml/100g body weight) 6.02±0.52 12.23±2.53 0.044 
Water intake during one interval (ml/time) 0.07±0.01 0.07±0.01 0.582 
Energy expenditure (kcal/h) 0.49±0.01 0.44±0.02 0.034 
Energy expenditure (kcal/h/100g body weight) 1.5±0.03 1.88±0.05 0.000 
Energy expenditure (kcal/h/cm2 body surface) 0.005±0 0.006±0 0.002 
RER 0.93±0.02 1.07±0.02 0.000 
VO2 3026.41±63.52 3667.4±102.96 0.000 
VCO2 2820.32±65.79 3931.53±129.81 0.000 
Ambulatory activity 15133.5±1779.52 16968±2483.48 0.562 
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Supplementary Table S5 | Energy balance in wild-type (WT) and M3KO mice at 11 months 
of age. Data expressed as mean±SEM. Independent t-test was used for all comparisons. U –
test were used if normality assumptions were not met (denoted U). 
 
Parameters WT (n=8) M3KO (n=8) p-value (two-tailed) 
24 Hours 
Food Intake (g) 3.04±0.56 3.1±0.25 0.003u 
Food Intake (g/100g body weight) 8.78±1.99 12.03±0.73 0.000u 
Calories intake (kcal) 7.82±1.43 7.97±0.64 0.003u 
Calories intake (kcal/100g body weight) 22.56±5.12 30.91±1.87 0.000u 
Number of meals 72.63±9.47 46.38±16.07 0.181 
Meal size (g/meal) 0.04±0.01 0.32±0.18 0.328u 
Meal size (kcal/meal) 0.11±0.02 0.83±0.47 0.328u 
Meal duration (min) 38.1±3.65 36.63±13.44 0.918 
Meal duration (min/meal) 0.61±0.1 1.09±0.34 0.442u 
Intermeal interval (min) 21.91±3.23 112.61±56.13 0.505u 
Satiety ratio (min/g) 529.99±62.39 438.87±46.99 0.263 
Rate of eating (g/min) 0.08±0.01 0.4±0.22 0.574u 
Water intake (mL) 2.28±0.27 3.74±0.41 0.010 
Water intake (ml/100g body weight) 6.48±1 14.62±1.71 0.001 
Water intake during one interval (ml/time) 0.06±0.01 0.06±0 0.515 
Energy expenditure (kcal/h) 0.42±0.04 0.42±0.02 0.970 
Energy expenditure (kcal/h/100g body weight) 1.15±0.11 1.64±0.03 0.003 
Energy expenditure (kcal/h/cm2 body surface) 0.004±0 0.005±0 0.023 
RER 0.85±0.02 1.04±0.02 0.000u 
VO2 2363.17±228.09 3199.54±61.23 0.008 
VCO2 2021.22±198.3 3357.79±66.95 0.000 
Ambulatory activity 17856.83±976.98 17046.83±2190.65 0.743 
     
 
Parameters WT (n=8) M3KO (n=8) p-value (two-tailed) 
Light Phase 
Food Intake (g) 1.19±0.31 0.77±0.17 0.263 
Food Intake (g/100g body weight) 3.48±1.06 3.02±0.7 0.723 
Calories intake (kcal) 3.06±0.81 1.99±0.45 0.263 
Calories intake (kcal/100g body weight) 8.95±2.72 7.77±1.81 0.723 
Number of meals 26.5±5.95 22.25±7.98 0.676 
Meal size (g/meal) 0.05±0.01 0.18±0.09 0.199 
Meal size (kcal/meal) 0.13±0.02 0.45±0.23 0.199 
Meal duration (min) 12.07±1.84 14.7±7.58 0.028u 
Meal duration (min/meal) 0.64±0.13 0.73±0.25 0.753 
Intermeal interval (min) 39.93±10.26 151.88±61.13 0.028u 
Satiety ratio (min/g) 774.76±132 1399.58±662.91 0.007u 
Rate of eating (g/min) 0.1±0.03 0.34±0.17 0.219 
Water intake (mL) 0.76±0.14 0.78±0.2 0.950 
Water intake (ml/100g body weight) 2.14±0.42 2.97±0.72 0.340 
Water intake during one interval (ml/time) 0.05±0.01 0.05±0.01 0.717 
Energy expenditure (kcal/h) 0.38±0.03 0.37±0.02 0.737 
Energy expenditure (kcal/h/100g body weight) 1.05±0.1 1.43±0.04 0.005 
Energy expenditure (kcal/h/cm2 body surface) 0.004±0 0.005±0 0.328u 
RER 0.83±0.02 0.97±0.03 0.028u 
VO2 2167.93±221.84 2841.45±79.9 0.013 
VCO2 1794.32±182.51 2755.23±105.23 0.000 
Ambulatory activity 3857.33±425.65 4110.5±656.7 0.753 
     
 
Parameters WT (n=8) M3KO (n=8) p-value (two-tailed) 
Dark Phase 
Food Intake (g) 1.85±0.27 2.33±0.24 0.645u 
Food Intake (g/100g body weight) 5.3±0.99 9±0.88 0.442u 
Calories intake (kcal) 4.75±0.69 5.98±0.63 0.645u 
Calories intake (kcal/100g body weight) 13.61±2.54 23.14±2.26 0.442u 
Number of meals 46.13±5.85 24.13±8.36 0.049 
Meal size (g/meal) 0.05±0.01 0.52±0.36 0.083u 
Meal size (kcal/meal) 0.12±0.02 1.33±0.92 0.083u 
Meal duration (min) 26.03±3.47 21.93±6.37 0.581 
Meal duration (min/meal) 0.65±0.12 1.33±0.45 0.328u 
Intermeal interval (min) 16.26±1.8 82.67±40.89 0.195u 
Satiety ratio (min/g) 424.69±65.51 298.51±48.29 0.143 
Rate of eating (g/min) 0.07±0.01 0.49±0.29 0.328u 
Water intake (mL) 1.52±0.17 2.97±0.42 0.007 
Water intake (ml/100g body weight) 4.34±0.67 11.65±1.9 0.028u 
Water intake during one interval (ml/time) 0.06±0 0.06±0 0.366 
Energy expenditure (kcal/h) 0.46±0.05 0.48±0.03 0.745 
Energy expenditure (kcal/h/100g body weight) 1.25±0.12 1.85±0.06 0.000u 
Energy expenditure (kcal/h/cm2 body surface) 0.005±0 0.006±0 0.009 
RER 0.88±0.02 1.11±0.02 0.000u 
VO2 2558.41±238.86 3557.62±107.81 0.000u 
VCO2 2248.11±216.3 3960.36±137.2 0.000 
Ambulatory activity 13999.5±762.25 12936.33±1838.05 0.610 
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Supplementary Table S6 | Energy balance in wild-type (WT) and M3KO mice at 15 months 
of age. Data expressed as mean±SEM. Independent t-test was used for all comparisons. U –
test were used if normality assumptions were not met (denoted U). 
 
Parameters WT (n=8) M3KO (n=8) p-value (two-tailed) 
24 Hours 
Food Intake (g) 2.98±0.51 3.73±0.5 0.304 
Food Intake (g/100g body weight) 8.25±1.85 13.41±2.17 0.092 
Calories intake (kcal) 7.65±1.3 9.59±1.28 0.304 
Calories intake (kcal/100g body weight) 21.2±4.75 34.46±5.57 0.092 
Number of meals 93±21.96 42.88±13.88 0.959u 
Meal size (g/meal) 0.04±0.01 0.22±0.1 0.015 u 
Meal size (kcal/meal) 0.1±0.02 0.57±0.26 0.015u 
Meal duration (min) 53.23±12.81 58.31±20.9 0.015u 
Meal duration (min/meal) 0.76±0.2 2.48±0.88 0.092 
Intermeal interval (min) 20.42±4.11 82.2±32.6 0.234u 
Satiety ratio (min/g) 611.73±149.57 413.72±82.69 0.021u 
Rate of eating (g/min) 0.07±0.02 0.11±0.03 1.000u 
Water intake (mL) 2.37±0.38 4.67±0.94 0.040 
Water intake (ml/100g body weight) 6.49±1.35 16.83±3.84 0.000u 
Water intake during one interval (ml/time) 0.08±0.02 0.08±0.02 0.905 
Energy expenditure (kcal/h) 0.42±0.04 0.44±0.02 0.679 
Energy expenditure (kcal/h/100g body weight) 1.09±0.1 1.54±0.08 0.003 
Energy expenditure (kcal/h/cm2 body surface) 0.004±0 0.005±0 0.000u 
RER 0.82±0.03 1.01±0.02 0.001u 
VO2 2263.56±213.94 3041.98±161.91 0.012 
VCO2 1837.37±157.2 3114.74±180.56 0.000 
Ambulatory activity 18779±3267.54 14149.83±3576.57 0.362 
     
 
Parameters WT (n=8) M3KO (n=8) p-value (two-tailed) 
Light Phase 
Food Intake (g) 1.09±0.15 0.66±0.12 0.043 
Food Intake (g/100g body weight) 2.9±0.45 2.39±0.46 0.440 
Calories intake (kcal) 2.8±0.39 1.7±0.31 0.043 
Calories intake (kcal/100g body weight) 7.47±1.16 6.15±1.19 0.440 
Number of meals 35.75±10.68 19.38±6.89 0.219 
Meal size (g/meal) 0.04±0.01 0.12±0.05 0.180 
Meal size (kcal/meal) 0.11±0.02 0.3±0.13 0.180 
Meal duration (min) 15.11±5 16.64±6.38 0.021u 
Meal duration (min/meal) 0.74±0.23 2.33±1.02 0.166 
Intermeal interval (min) 30.78±7.92 118.35±45.17 0.095 
Satiety ratio (min/g) 733.59±130.19 1281.43±340.48 0.050u 
Rate of eating (g/min) 0.15±0.05 0.07±0.01 0.328u 
Water intake (mL) 0.82±0.16 0.78±0.28 0.908 
Water intake (ml/100g body weight) 2.24±0.51 2.83±1.06 0.626 
Water intake during one interval (ml/time) 0.08±0.02 0.05±0.01 0.279u 
Energy expenditure (kcal/h) 0.38±0.04 0.39±0.02 0.946 
Energy expenditure (kcal/h/100g body weight) 0.99±0.08 1.36±0.07 0.005 
Energy expenditure (kcal/h/cm2 body surface) 0.004±0 0.005±0 0.034 
RER 0.82±0.02 0.96±0.02 0.000 
VO2 2056±180.32 2716.36±141.6 0.012 
VCO2 1664.28±131.51 2608.84±144.57 0.000 
Ambulatory activity 4753±486.8 4258±1153.65 0.701 
     
 
Parameters WT (n=8) M3KO (n=8) p-value (two-tailed) 
Dark Phase 
Food Intake (g) 1.88±0.46 3.07±0.4 0.072 
Food Intake (g/100g body weight) 5.34±1.64 11.02±1.77 0.034 
Calories intake (kcal) 4.84±1.18 7.89±1.03 0.072 
Calories intake (kcal/100g body weight) 13.74±4.22 28.32±4.55 0.034 
Number of meals 57.25±11.66 23.5±8.4 0.034 
Meal size (g/meal) 0.03±0.01 0.32±0.15 0.001u 
Meal size (kcal/meal) 0.09±0.02 0.83±0.39 0.001u 
Meal duration (min) 38.12±9.03 41.68±15.35 0.845 
Meal duration (min/meal) 0.79±0.19 2.62±0.8 0.057 
Intermeal interval (min) 15.16±2.79 69.65±27.16 0.105u 
Satiety ratio (min/g) 586.3±170.24 231.18±42.9 0.002u 
Rate of eating (g/min) 0.06±0.02 0.14±0.03 0.105u 
Water intake (mL) 1.56±0.28 3.89±0.72 0.014 
Water intake (ml/100g body weight) 4.24±0.95 14±2.99 0.028u 
Water intake during one interval (ml/time) 0.08±0.02 0.09±0.02 0.955 
Energy expenditure (kcal/h) 0.46±0.04 0.49±0.02 0.500 
Energy expenditure (kcal/h/100g body weight) 1.19±0.12 1.73±0.1 0.003 
Energy expenditure (kcal/h/cm2 body surface) 0.005±0 0.006±0 0.015 
RER 0.82±0.03 1.07±0.02 0.000u 
VO2 2471.12±250.41 3367.61±185.81 0.012 
VCO2 2010.47±185 3620.64±222.35 0.000 
Ambulatory activity 14026±2998.34 9891.83±2435.21 0.310 
 
 
